⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Genorare B.V. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Genorare B.V.
↗Amsterdam, Netherlands
Genorare is a Netherlands-based health-tech startup that aims to shorten the diagnostic journey for rare disease patients. The company utilizes an AI-powered platform that integrates Large Language Models (LLMs), predictive analytics, and Fully Homomorphic Encryption (FHE) to analyze genomic data, EHRs, and lab results securely without decrypting sensitive patient information.
Founded in collaboration with NLC Health Ventures, the company provides diagnostic support tools for clinicians and clinical trial matching services for pharmaceutical partners. By enabling secure, real-time insights, Genorare seeks to improve patient stratification and precision enrollment in rare disease research.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:
Industry:Digital Health
Sub-Industry:AI-powered Diagnostics / Rare Disease
SIZE & FINANCIALS
Employees:1-50
Founded:2025
Ownership:private
Status:operating
FUNDING
Stage:Pre-Seed
Investors:NLC Health Ventures, Health Impact Fund
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (Software/Platform)
Modalities:Digital Health Platform
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:NLC Health Ventures (Venture Builder)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Dr. Quy Vo-Reinhard - CEO
Scientific Founders:Dr. Quy Vo-Reinhard
LINKS
Website:genorare.net
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Genorare B.V.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.